The course of depressive symptoms in early Parkinson's disease
Identifieur interne : 000A19 ( Main/Corpus ); précédent : 000A18; suivant : 000A20The course of depressive symptoms in early Parkinson's disease
Auteurs : Bernard Ravina ; Jordan Elm ; Richard Camicioli ; Peter G. Como ; Laura Marsh ; Joseph Jankovic ; Daniel WeintraubSource :
- Movement Disorders [ 0885-3185 ] ; 2009-07-15.
English descriptors
- KwdEn :
Abstract
Little is known about the course of depressive symptoms in Parkinson's disease (PD). We studied the course of clinically significant depressive symptoms using data from two clinical trials that followed 413 early, untreated PD subjects for 12 to 18 months. We measured depressive symptoms with the 15‐item geriatric depression scale (GDS‐15); a score of ≥5 indicates clinically significant depressive symptoms. We used a time‐dependent Cox model to examine the association between demographic variables, PD severity, and medication use on the time to resolution of depressive symptoms. One hundred fourteen of 413 (27.6%) subjects were screened positive for depression during the study, with a median GDS‐15 score of 6, indicating mild symptoms. Within 6 months, 47% of subjects experienced remission of clinically significant depressive symptoms. Subjects with mild depressive symptoms were more likely to develop moderate to severe depressive symptoms (GDS ≥ 10) than those without prior symptoms (relative risk = 6.16). Increasing severity of depressive symptoms, older age, and longer PD duration predicted a lower likelihood of symptom resolution (hazard ratios 0.83–0.92). Mild depressive symptoms have a variable course, with remission and development of more sustained and severe symptoms occurring over time. More severe depressive symptoms may herald a protracted course. © 2009 Movement Disorder Society
Url:
DOI: 10.1002/mds.22572
Links to Exploration step
ISTEX:A23D1AF2BE33F703ED27BB68C71DB1CB46737B5DLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The course of depressive symptoms in early Parkinson's disease</title><author><name sortKey="Ravina, Bernard" sort="Ravina, Bernard" uniqKey="Ravina B" first="Bernard" last="Ravina">Bernard Ravina</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Elm, Jordan" sort="Elm, Jordan" uniqKey="Elm J" first="Jordan" last="Elm">Jordan Elm</name><affiliation><mods:affiliation>Department of Biostatistics, Medical University of South Carolina, Charleston, South Carolina, USA</mods:affiliation></affiliation></author><author><name sortKey="Camicioli, Richard" sort="Camicioli, Richard" uniqKey="Camicioli R" first="Richard" last="Camicioli">Richard Camicioli</name><affiliation><mods:affiliation>Department of Neurology, University of Alberta, Edmonton, Canada</mods:affiliation></affiliation></author><author><name sortKey="Como, Peter G" sort="Como, Peter G" uniqKey="Como P" first="Peter G." last="Como">Peter G. Como</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name><affiliation><mods:affiliation>Department of Psychiatry, Johns Hopkins University, Baltimore, Maryland, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA</mods:affiliation></affiliation></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation><mods:affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas, USA</mods:affiliation></affiliation></author><author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name><affiliation><mods:affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A23D1AF2BE33F703ED27BB68C71DB1CB46737B5D</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.22572</idno><idno type="url">https://api.istex.fr/document/A23D1AF2BE33F703ED27BB68C71DB1CB46737B5D/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000A19</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The course of depressive symptoms in early Parkinson's disease</title><author><name sortKey="Ravina, Bernard" sort="Ravina, Bernard" uniqKey="Ravina B" first="Bernard" last="Ravina">Bernard Ravina</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Elm, Jordan" sort="Elm, Jordan" uniqKey="Elm J" first="Jordan" last="Elm">Jordan Elm</name><affiliation><mods:affiliation>Department of Biostatistics, Medical University of South Carolina, Charleston, South Carolina, USA</mods:affiliation></affiliation></author><author><name sortKey="Camicioli, Richard" sort="Camicioli, Richard" uniqKey="Camicioli R" first="Richard" last="Camicioli">Richard Camicioli</name><affiliation><mods:affiliation>Department of Neurology, University of Alberta, Edmonton, Canada</mods:affiliation></affiliation></author><author><name sortKey="Como, Peter G" sort="Como, Peter G" uniqKey="Como P" first="Peter G." last="Como">Peter G. Como</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name><affiliation><mods:affiliation>Department of Psychiatry, Johns Hopkins University, Baltimore, Maryland, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA</mods:affiliation></affiliation></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation><mods:affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas, USA</mods:affiliation></affiliation></author><author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name><affiliation><mods:affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-07-15">2009-07-15</date><biblScope unit="volume">24</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1306">1306</biblScope><biblScope unit="page" to="1311">1311</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">A23D1AF2BE33F703ED27BB68C71DB1CB46737B5D</idno><idno type="DOI">10.1002/mds.22572</idno><idno type="ArticleID">MDS22572</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>clinical course</term><term>depression</term><term>prognosis</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Little is known about the course of depressive symptoms in Parkinson's disease (PD). We studied the course of clinically significant depressive symptoms using data from two clinical trials that followed 413 early, untreated PD subjects for 12 to 18 months. We measured depressive symptoms with the 15‐item geriatric depression scale (GDS‐15); a score of ≥5 indicates clinically significant depressive symptoms. We used a time‐dependent Cox model to examine the association between demographic variables, PD severity, and medication use on the time to resolution of depressive symptoms. One hundred fourteen of 413 (27.6%) subjects were screened positive for depression during the study, with a median GDS‐15 score of 6, indicating mild symptoms. Within 6 months, 47% of subjects experienced remission of clinically significant depressive symptoms. Subjects with mild depressive symptoms were more likely to develop moderate to severe depressive symptoms (GDS ≥ 10) than those without prior symptoms (relative risk = 6.16). Increasing severity of depressive symptoms, older age, and longer PD duration predicted a lower likelihood of symptom resolution (hazard ratios 0.83–0.92). Mild depressive symptoms have a variable course, with remission and development of more sustained and severe symptoms occurring over time. More severe depressive symptoms may herald a protracted course. © 2009 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Bernard Ravina MD, MSCE</name><affiliations><json:string>Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA</json:string></affiliations></json:item><json:item><name>Jordan Elm MA</name><affiliations><json:string>Department of Biostatistics, Medical University of South Carolina, Charleston, South Carolina, USA</json:string></affiliations></json:item><json:item><name>Richard Camicioli MD</name><affiliations><json:string>Department of Neurology, University of Alberta, Edmonton, Canada</json:string></affiliations></json:item><json:item><name>Peter G. Como PhD</name><affiliations><json:string>Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA</json:string></affiliations></json:item><json:item><name>Laura Marsh MD</name><affiliations><json:string>Department of Psychiatry, Johns Hopkins University, Baltimore, Maryland, USA</json:string><json:string>Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA</json:string></affiliations></json:item><json:item><name>Joseph Jankovic MD</name><affiliations><json:string>Department of Neurology, Baylor College of Medicine, Houston, Texas, USA</json:string></affiliations></json:item><json:item><name>Daniel Weintraub MD</name><affiliations><json:string>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA</json:string><json:string>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>depression</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>clinical course</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>prognosis</value></json:item></subject><articleId><json:string>MDS22572</json:string></articleId><language><json:string>eng</json:string></language><abstract>Little is known about the course of depressive symptoms in Parkinson's disease (PD). We studied the course of clinically significant depressive symptoms using data from two clinical trials that followed 413 early, untreated PD subjects for 12 to 18 months. We measured depressive symptoms with the 15‐item geriatric depression scale (GDS‐15); a score of ≥5 indicates clinically significant depressive symptoms. We used a time‐dependent Cox model to examine the association between demographic variables, PD severity, and medication use on the time to resolution of depressive symptoms. One hundred fourteen of 413 (27.6%) subjects were screened positive for depression during the study, with a median GDS‐15 score of 6, indicating mild symptoms. Within 6 months, 47% of subjects experienced remission of clinically significant depressive symptoms. Subjects with mild depressive symptoms were more likely to develop moderate to severe depressive symptoms (GDS ≥ 10) than those without prior symptoms (relative risk = 6.16). Increasing severity of depressive symptoms, older age, and longer PD duration predicted a lower likelihood of symptom resolution (hazard ratios 0.83–0.92). Mild depressive symptoms have a variable course, with remission and development of more sustained and severe symptoms occurring over time. More severe depressive symptoms may herald a protracted course. © 2009 Movement Disorder Society</abstract><qualityIndicators><score>5.844</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>4</keywordCount><abstractCharCount>1414</abstractCharCount><pdfWordCount>3372</pdfWordCount><pdfCharCount>22356</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>206</abstractWordCount></qualityIndicators><title>The course of depressive symptoms in early Parkinson's disease</title><genre><json:string>article</json:string></genre><host><volume>24</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>6</total><last>1311</last><first>1306</first></pages><issn><json:string>0885-3185</json:string></issn><issue>9</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2009</publicationDate><copyrightDate>2009</copyrightDate><doi><json:string>10.1002/mds.22572</json:string></doi><id>A23D1AF2BE33F703ED27BB68C71DB1CB46737B5D</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/A23D1AF2BE33F703ED27BB68C71DB1CB46737B5D/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/A23D1AF2BE33F703ED27BB68C71DB1CB46737B5D/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/A23D1AF2BE33F703ED27BB68C71DB1CB46737B5D/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">The course of depressive symptoms in early Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2009</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: Nothing to report.</note><note>NIH</note><note>National Institute of Neurological Disorders and Stroke - No. U01NS043127; No. U01NS043128;</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">The course of depressive symptoms in early Parkinson's disease</title><author><persName><forename type="first">Bernard</forename><surname>Ravina</surname></persName><roleName type="degree">MD, MSCE</roleName><note type="correspondence"><p>Correspondence: 1351 Mt. Hope Ave., Suite 223, Rochester, NY 14620</p></note><affiliation>Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA</affiliation></author><author><persName><forename type="first">Jordan</forename><surname>Elm</surname></persName><roleName type="degree">MA</roleName><affiliation>Department of Biostatistics, Medical University of South Carolina, Charleston, South Carolina, USA</affiliation></author><author><persName><forename type="first">Richard</forename><surname>Camicioli</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, University of Alberta, Edmonton, Canada</affiliation></author><author><persName><forename type="first">Peter G.</forename><surname>Como</surname></persName><roleName type="degree">PhD</roleName><affiliation>Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA</affiliation></author><author><persName><forename type="first">Laura</forename><surname>Marsh</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Psychiatry, Johns Hopkins University, Baltimore, Maryland, USA</affiliation><affiliation>Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA</affiliation></author><author><persName><forename type="first">Joseph</forename><surname>Jankovic</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas, USA</affiliation></author><author><persName><forename type="first">Daniel</forename><surname>Weintraub</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA</affiliation><affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-07-15"></date><biblScope unit="volume">24</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1306">1306</biblScope><biblScope unit="page" to="1311">1311</biblScope></imprint></monogr><idno type="istex">A23D1AF2BE33F703ED27BB68C71DB1CB46737B5D</idno><idno type="DOI">10.1002/mds.22572</idno><idno type="ArticleID">MDS22572</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2009</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Little is known about the course of depressive symptoms in Parkinson's disease (PD). We studied the course of clinically significant depressive symptoms using data from two clinical trials that followed 413 early, untreated PD subjects for 12 to 18 months. We measured depressive symptoms with the 15‐item geriatric depression scale (GDS‐15); a score of ≥5 indicates clinically significant depressive symptoms. We used a time‐dependent Cox model to examine the association between demographic variables, PD severity, and medication use on the time to resolution of depressive symptoms. One hundred fourteen of 413 (27.6%) subjects were screened positive for depression during the study, with a median GDS‐15 score of 6, indicating mild symptoms. Within 6 months, 47% of subjects experienced remission of clinically significant depressive symptoms. Subjects with mild depressive symptoms were more likely to develop moderate to severe depressive symptoms (GDS ≥ 10) than those without prior symptoms (relative risk = 6.16). Increasing severity of depressive symptoms, older age, and longer PD duration predicted a lower likelihood of symptom resolution (hazard ratios 0.83–0.92). Mild depressive symptoms have a variable course, with remission and development of more sustained and severe symptoms occurring over time. More severe depressive symptoms may herald a protracted course. © 2009 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>depression</term></item><item><term>clinical course</term></item><item><term>prognosis</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2008-09-09">Received</change><change when="2009-03-06">Registration</change><change when="2009-07-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/A23D1AF2BE33F703ED27BB68C71DB1CB46737B5D/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="90"><doi origin="wiley" registered="yes">10.1002/mds.v24:9</doi><numberingGroup><numbering type="journalVolume" number="24">24</numbering><numbering type="journalIssue">9</numbering></numberingGroup><coverDate startDate="2009-07-15">15 July 2009</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="70" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22572</doi><idGroup><id type="unit" value="MDS22572"></id></idGroup><countGroup><count type="pageTotal" number="6"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2009 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2008-09-09"></event><event type="manuscriptRevised" date="2008-12-17"></event><event type="manuscriptAccepted" date="2009-03-06"></event><event type="publishedOnlineEarlyUnpaginated" date="2009-05-01"></event><event type="firstOnline" date="2009-05-01"></event><event type="publishedOnlineFinalForm" date="2009-07-24"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1306</numbering><numbering type="pageLast">1311</numbering></numberingGroup><correspondenceTo>1351 Mt. Hope Ave., Suite 223, Rochester, NY 14620</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22572.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="28"></count><count type="wordTotal" number="4400"></count></countGroup><titleGroup><title type="main" xml:lang="en">The course of depressive symptoms in early Parkinson's disease<link href="#fn1"></link></title><title type="short" xml:lang="en">Depressive Symptoms in Early PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Bernard</givenNames><familyName>Ravina</familyName><degrees>MD, MSCE</degrees></personName><contactDetails><email>Bernard.ravina@ctcc.rochester.edu</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Jordan</givenNames><familyName>Elm</familyName><degrees>MA</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Richard</givenNames><familyName>Camicioli</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Peter G.</givenNames><familyName>Como</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af4 #af5"><personName><givenNames>Laura</givenNames><familyName>Marsh</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Joseph</givenNames><familyName>Jankovic</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af7 #af8"><personName><givenNames>Daniel</givenNames><familyName>Weintraub</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Department of Biostatistics, Medical University of South Carolina, Charleston, South Carolina, USA</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="CA" type="organization"><unparsedAffiliation>Department of Neurology, University of Alberta, Edmonton, Canada</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>Department of Psychiatry, Johns Hopkins University, Baltimore, Maryland, USA</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas, USA</unparsedAffiliation></affiliation><affiliation xml:id="af7" countryCode="US" type="organization"><unparsedAffiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA</unparsedAffiliation></affiliation><affiliation xml:id="af8" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">depression</keyword><keyword xml:id="kwd3">clinical course</keyword><keyword xml:id="kwd4">prognosis</keyword></keywordGroup><fundingInfo><fundingAgency>NIH</fundingAgency></fundingInfo><fundingInfo><fundingAgency>National Institute of Neurological Disorders and Stroke</fundingAgency><fundingNumber>U01NS043127</fundingNumber><fundingNumber>U01NS043128</fundingNumber></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Little is known about the course of depressive symptoms in Parkinson's disease (PD). We studied the course of clinically significant depressive symptoms using data from two clinical trials that followed 413 early, untreated PD subjects for 12 to 18 months. We measured depressive symptoms with the 15‐item geriatric depression scale (GDS‐15); a score of ≥5 indicates clinically significant depressive symptoms. We used a time‐dependent Cox model to examine the association between demographic variables, PD severity, and medication use on the time to resolution of depressive symptoms. One hundred fourteen of 413 (27.6%) subjects were screened positive for depression during the study, with a median GDS‐15 score of 6, indicating mild symptoms. Within 6 months, 47% of subjects experienced remission of clinically significant depressive symptoms. Subjects with mild depressive symptoms were more likely to develop moderate to severe depressive symptoms (GDS ≥ 10) than those without prior symptoms (relative risk = 6.16). Increasing severity of depressive symptoms, older age, and longer PD duration predicted a lower likelihood of symptom resolution (hazard ratios 0.83–0.92). Mild depressive symptoms have a variable course, with remission and development of more sustained and severe symptoms occurring over time. More severe depressive symptoms may herald a protracted course. © 2009 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Potential conflict of interest: Nothing to report.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>The course of depressive symptoms in early Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Depressive Symptoms in Early PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>The course of depressive symptoms in early Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Bernard</namePart><namePart type="family">Ravina</namePart><namePart type="termsOfAddress">MD, MSCE</namePart><affiliation>Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA</affiliation><description>Correspondence: 1351 Mt. Hope Ave., Suite 223, Rochester, NY 14620</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jordan</namePart><namePart type="family">Elm</namePart><namePart type="termsOfAddress">MA</namePart><affiliation>Department of Biostatistics, Medical University of South Carolina, Charleston, South Carolina, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Richard</namePart><namePart type="family">Camicioli</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Alberta, Edmonton, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Peter G.</namePart><namePart type="family">Como</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Laura</namePart><namePart type="family">Marsh</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Psychiatry, Johns Hopkins University, Baltimore, Maryland, USA</affiliation><affiliation>Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Joseph</namePart><namePart type="family">Jankovic</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Daniel</namePart><namePart type="family">Weintraub</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA</affiliation><affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2009-07-15</dateIssued><dateCaptured encoding="w3cdtf">2008-09-09</dateCaptured><dateValid encoding="w3cdtf">2009-03-06</dateValid><copyrightDate encoding="w3cdtf">2009</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">2</extent><extent unit="tables">2</extent><extent unit="references">28</extent><extent unit="words">4400</extent></physicalDescription><abstract lang="en">Little is known about the course of depressive symptoms in Parkinson's disease (PD). We studied the course of clinically significant depressive symptoms using data from two clinical trials that followed 413 early, untreated PD subjects for 12 to 18 months. We measured depressive symptoms with the 15‐item geriatric depression scale (GDS‐15); a score of ≥5 indicates clinically significant depressive symptoms. We used a time‐dependent Cox model to examine the association between demographic variables, PD severity, and medication use on the time to resolution of depressive symptoms. One hundred fourteen of 413 (27.6%) subjects were screened positive for depression during the study, with a median GDS‐15 score of 6, indicating mild symptoms. Within 6 months, 47% of subjects experienced remission of clinically significant depressive symptoms. Subjects with mild depressive symptoms were more likely to develop moderate to severe depressive symptoms (GDS ≥ 10) than those without prior symptoms (relative risk = 6.16). Increasing severity of depressive symptoms, older age, and longer PD duration predicted a lower likelihood of symptom resolution (hazard ratios 0.83–0.92). Mild depressive symptoms have a variable course, with remission and development of more sustained and severe symptoms occurring over time. More severe depressive symptoms may herald a protracted course. © 2009 Movement Disorder Society</abstract><note type="content">*Potential conflict of interest: Nothing to report.</note><note type="funding">NIH</note><note type="funding">National Institute of Neurological Disorders and Stroke - No. U01NS043127; No. U01NS043128; </note><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>depression</topic><topic>clinical course</topic><topic>prognosis</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><detail type="issue"><caption>no.</caption><number>9</number></detail><extent unit="pages"><start>1306</start><end>1311</end><total>6</total></extent></part></relatedItem><identifier type="istex">A23D1AF2BE33F703ED27BB68C71DB1CB46737B5D</identifier><identifier type="DOI">10.1002/mds.22572</identifier><identifier type="ArticleID">MDS22572</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2009 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A19 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000A19 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:A23D1AF2BE33F703ED27BB68C71DB1CB46737B5D
|texte= The course of depressive symptoms in early Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |